3Mantovani A et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin lmmunol, 2008, 28:1-3.
4Tillet WS et al. Serological reaction in pneumonia with a non- protein somatic fraction of pnemoncoccus. J Exp Med, 1930, 52: 561-571.
5MacLeod CM et al. The occurrence during acute infections of a protein not normally present in the blood II, isolation and properties of the reactive protein. J Exp Med, 1943, 73:183-191.
6Dhingra R et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med, 2007, 120:1054-1062.
7Willeke F et al. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer, 2006, 42:2639-2646.
8Miyake K et al. Serum evaluation of soluble interferon-α/βreceptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine, 201 O, 49:251-255.
9Wang CS et al. C-reactive protein and malignancy: clinic- pathological association and therapeutic implication. Chang Gung MedJ, 2009, 32:471-482.
10Nagaoka Set al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int, 2007, 27:1091-1097.
